Drugs / CX-2051
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06265688 | Apr 2024 → Nov 2027 expected | cancer | CytomX Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-16 | CytomX Therapeutics | Results CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update cytomx.com ↗
Announced positive data update from Phase 1 dose expansion study of Varseta-M in patients with advanced colorectal cancer (CRC). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-16 | CytomX Therapeutics | CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update cytomx.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CX-2051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06265688 ↗ |